Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV + hMPV combined vaccine (Shenzhen Kangtai)
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The RSV + hMPV combined vaccine is a preclinical-stage combination vaccine being developed by Shenzhen Kangtai Biological Products (BioKangtai). This vaccine is intended to prevent respiratory infections caused by both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), which are significant causes of morbidity and mortality in vulnerable populations such as infants and the elderly. As of the current pipeline status, the specific vaccine platform (e.g., mRNA, protein subunit, or inactivated) and adjuvant system have not been disclosed. The product represents an effort to streamline immunization schedules by targeting two major respiratory pathogens in a single formulation.
- Other names
- respiratory syncytial virus + human metapneumovirus combined vaccine呼吸道合胞病毒（RSV）和人偏肺病毒（hMPV）联合疫苗
02
Targets
hMPV (Human metapneumovirus)
Beyond the preview
Go deeper on RSV + hMPV combined vaccine (Shenzhen Kangtai).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV + hMPV combined vaccine (Shenzhen Kangtai).